Dr. Rita A Jablonski, PhD
Claim this profileStudies Dementia
Studies Care-resistant Behavior
1 reported clinical trial
1 drug studied
Clinical Trials Rita A Jablonski, PhD is currently running
More about Rita A Jablonski, PhD
Clinical Trial Related2 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical TrialTreatments Rita A Jablonski, PhD has experience with
- CuRB-IT
Breakdown of trials Rita A Jablonski, PhD has run
Dementia
Care-resistant Behavior
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rita A Jablonski, PhD specialize in?
Rita A Jablonski, PhD focuses on Dementia and Care-resistant Behavior. In particular, much of their work with Dementia has involved treating patients, or patients who are undergoing treatment.
Is Rita A Jablonski, PhD currently recruiting for clinical trials?
Yes, Rita A Jablonski, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Rita A Jablonski, PhD has studied deeply?
Yes, Rita A Jablonski, PhD has studied treatments such as CuRB-IT.
What is the best way to schedule an appointment with Rita A Jablonski, PhD?
Apply for one of the trials that Rita A Jablonski, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.